快速查找

Global
吉凯基因 新药研发
新药研发

新药研发聚焦于细胞治疗、基因治疗、抗体药物等创新药物的开发，致力于与临床医生共同将具有重大临床意义的科学研究进行临床转化，开发能够解决临床迫切需求的治疗产品。

目前已经建立起包含CAR-T、TCR-T等细胞治疗项目，AAV基因治疗项目以及单克隆抗体项目在内的完整的开发管线，并与多名领域带头人签署了长期的深度合作协议。

研发管线

Cell Therapy

Program Indication
Target
Validation Lead Candidate Pre-IND IND Phase I Phase II
Program：GB5005Undisclosed Indication：Leukemia/Lymphoma

phase：IND

Program：GB5010Undisclosed Indication：Multiple Myeloma

phase：Pre-IND

Program：*GB30101
View more
 Indication：Pancreatic Cancer

phase：Pre-IND

Program：*GB30103
View more
 Indication：Pancreatic Cancer

phase：Pre-IND

Program：GB3015Undisclosed Indication：Nasopharyngeal Carcinoma

phase：Pre-IND

Program：GB3007Undisclosed Indication：Synovial Sarcoma

phase：Pre-IND

Program：GB3016Undisclosed Indication：Solid Tumor

phase：Lead

Program：GB5017Undisclosed Indication：Leukemia/Lymphoma

phase：Lead

Antibody

Program Indication
Target
Validation Lead Candidate Pre-IND IND Phase I Phase II
Program：GB7008Undisclosed Indication：Ovarian Cancer

phase：Pre-IND

Program：*GB7001
View more
 Indication：Gastric Cancer

phase：Pre-IND

Program：GB70041Undisclosed Indication：Gastric Cancer

phase：Pre-IND

Program：GB7012Undisclosed Indication：Colon Cancer

phase：Pre-IND

Program：GB7007Undisclosed Indication：lung cancer/Synovial sarcoma

phase：Candidate

Program：GB7011
View more
 Indication：liver cancer/Mammary cancer

phase：Candidate

Program：GB7013Undisclosed Indication：Multiple Myeloma

phase：Candidate

Program：GB7015
View more
 Indication：Blood Cancer

phase：Candidate

Program：*GB7016Undisclosed Indication：Gastric Cancer

phase：Lead

Program：GB7017Undisclosed Indication：Solid Tumor

phase：Lead

Program：*GB7018Undisclosed Indication：Solid Tumor

phase：Target Validation

Partnership

Program Indication
Target
Validation Lead Candidate Pre-IND IND Phase I Phase II
Program：GB5001 Indication：Leukemia/Lymphoma

phase：IND

Program：GB7004 Indication：Gastric Cancer

phase：IND

Program：GB7002 Indication：Gastric Cancer

phase：IND

Program：GB5012 Indication：Colon Cancer

phase：Pre-IND

Program：GB7005 Indication：Blood Cancer

phase：Pre-IND

Program：GB5013 Indication：Colon Cancer

phase：Candidate

Program：GB7008 Indication：Ovarian Cancer

phase：Pre-IND

*First in class

合作伙伴

标题

内容